Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity (DOCS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Doximity (DOCS) Ahead of Earnings?

Ortho Clinical Diagnostics Holdings

OCDX vs. DOCS: Which Stock Is the Better Value Option?

OCDX or DOCS: Which Is the Better Value Stock Right Now?

Affirm

D.R. Horton

Disney

RingCentral

Five large-cap (market capital > $10 billion) stocks will report earnings results next week. These are: DHI, RNG, DOCS, DIS and AFRM.

5 Large-Cap Stocks Likely to Win Big on Earnings Next Week

Doximity's (DOCS) products like Doximity Dialer and Residency Navigator have been in focus and we expect both to have generated significant revenues during the fiscal second quarter.

What's in the Cards for Doximity (DOCS) in Q2 Earnings?

SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS) will announce financial results for its second quarter which ended September 30, 2021 after market close on November 9, 2021. Doximity will host a conference call and webcast that day at 2:00 p.m.

Doximity to Release Fiscal 2022 Second Quarter Results on November 9, 2021

CVS Health

Humana

All three of these telehealth companies are already profitable and have solid financials.

3 Leading Telehealth Stocks to Buy in 2021 and Beyond

Atea Pharmaceuticals

10X Genomics

Our trio of contributors offer three COVID-19 stocks that will zoom higher, even as we emerge from the pandemic.

3 COVID Stocks That Can Turn $1,000 Into $10,000

It's hard to beat a strong network effect.

This Is Healthcare Platform Doximity's Biggest Advantage

Doximity has seen tremendous share price growth since its IPO, and if it succeeds in expanding its market opportunity, this could continue.

Up 68% from Its IPO, Is Doximity Still Worth Buying?

Teladoc

The healthcare industry is changing. Investors should adapt.

2 Top Telehealth Stocks to Buy for the Long Haul

Sales doubled in the most recent quarter.

Why Doximity Stock Soared 49% in August

An analyst only stated what had become relatively obvious about this young stock.

Why Doximity Plunged Nearly 13% Today

CarGurus

Marathon Petroleum

YUM! Brands

Coupang

Delek US Hlds

Pentair

Restaurant Brands

Ventas

The indexes all traded lower approaching the midday point on Thursday, after posting yet another round of new all-time highs on Wednesday.

Thursday Afternoon Analyst Upgrades and Downgrades: CarGurus, Marathon Petroleum, Yum Brands and More

SAN FRANCISCO, Aug. 26, 2021 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for medical professionals, today announced the release of its 2021-2022 Residency Navigator tool. Over 90% of graduating U.S. medical students join Doximity to use tools including Residency Navigator before earning their medical degree.

Doximity Announces 2021-2022 Residency Navigator

Align Technology

Veeva Systems

Find out why these companies are dominating in the niches they created.

3 Unstoppable Healthcare Stocks to Buy Now

American Well Corporation

UpHealth

Internet healthcare companies have seen their revenue skyrocket during the pandemic. What will the future bring?

Will Telehealth Stocks Thrive After COVID?

The networking and productivity platform for doctors is riding a wave of positive investor sentiment.

Why Doximity Stock Surged on Monday

SAN FRANCISCO, Aug. 23, 2021 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS) today announced that Anna Bryson, CFO, will participate in a virtual fireside chat at Morgan Stanley's 19th Annual Global Healthcare Conference on Thursday, Sept. 9, 2021, at 5:00 p.m.

Doximity to Participate in a Virtual Fireside Chat at Morgan Stanley's 19th Annual Global Healthcare Conference

Every analyst's target is higher than the current price.

Wall Street Thinks You Can't Lose With This Healthcare Stock

The stock price of Doximity Inc (NYSE: DOCS) increased by 32.6%. This is why it happened.

DOCS Stock Price Increased 32.6%: Why It Happened

The networking platform for healthcare professionals keeps exceeding expectations.

Here's Why Doximity Stock Is Surging Today

Doximity, Inc. (DOCS) CEO Jeff Tangney on Q2 2021 Results - Earnings Call Transcript

Doximity said revenue in the fiscal first quarter climbed to $72.7 million from $36.4 million a year earlier.

Doximity shares jump after digital health company says revenue doubled in first report since IPO

SAN FRANCISCO, Aug. 10, 2021 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2022 first quarter ended June 30, 2021. "We're pleased to report strong financial results in our first quarter as a public company -- triple digit revenue growth and record profit margins.

Doximity Announces Fiscal 2022 First Quarter Financial Results

This company is helping physicians improve their productivity with digital tools and a professional network.

News for Doximity Stock (DOCS)